Clinical-grade genetic testing for your patients

Our actionable results and complimentary access to our genetic counselors allow you to focus on what matters – patient care.

Order Color

Welcome to Color: affordable, accessible, and actionable

Patient focused genetic testing

Color’s low self-pay price and complimentary access to our genetic counselors make testing accessible for your patients.

Clinical-grade quality

Our validated test is performed in our CAP-accredited and CLIA-certified lab using Next Generation Sequencing methods and customized software tools.

Medically actionable results

Reports integrate relevant guidelines to help you develop a personalized screening and prevention plan for your patients.

Color partners with institutions such as:

Hereditary Cancer Test: $249 self-pay or insurance accepted

Hereditary Cancer Test, $249 self-pay

Survival rates for cancers covered by Color’s Hereditary Cancer Test increase dramatically when caught at an earlier and more treatable stage.

Our clinical-grade test includes:

  • Genetic risk analysis of 30 genes associated with common hereditary cancers
  • Guidelines to help you develop tailored screening and prevention plans for your patient
  • Complimentary access to our team of board-certified genetic counselors

Meet the Color provider community

Our providers believe in improving the lives of their patients.

Dr. Adashek, MD and Chris – Lutherville Timonium, Maryland

Dr. Adashek is a practicing obstetrician-gynecologist with over 30 years of experience and Chris is one of his patients. Chris’s results from the Hereditary Cancer Test indicated that she had an increased risk for ovarian, uterine, and other cancers. This prompted Dr. Adashek to work with Chris on a personalized screening and prevention plan.

Color’s lab, team, and processes generate results you can trust

Our CAP-accredited and CLIA-certified laboratory uses the newest technology, including Next Generation Sequencing, advanced liquid-handling robots, and customized software to ensure the integrity of our results.


Color performed blinded validation studies to assess the validity of our test, and all our genetic variants were detected with >99% accuracy. Read our validation white papers and other published studies and research posters.

Quality checked

The quality of every sample is checked multiple times as it moves through the sequencing and interpretation process.  A certified medical professional reviews every result before it is released.

State-of-the-art variant classification

Our Ph.D. and M.D. scientists use state-of-the-art tools to classify variants according to American College of Medical Genetics and Genomics (ACMG) guidelines.

Secondary confirmations

Likely pathogenic and pathogenic variants, copy number variations, insertions, and inversions are confirmed by an alternative technology according to Color’s internal protocols.*

Giving back

We believe everyone has the right to benefit from their own genetic information. To help make that vision a reality, Color brings genetic testing to underserved communities through Color for All. Our nonprofit Color Foundation provides funding for students and scientists studying the role of genetics in human disease via Color Research Grants.


The Color Research team partners with some of the world’s top research hospitals and clinics. Some of our partnerships include:



Our advisors and collaborators

Mary-Claire King, Ph.D.

Geneticist and Professor of Genome Sciences and Medicine at the University of Washington. Advisor, Scientific Collaborator

Tom Walsh, Ph.D.

Research Associate Professor of Medical Genetics at the University of Washington.Advisor, Scientific Collaborator

Laura van’t Veer, Ph.D.

Molecular Biologist and leader of the Breast Oncology Program at the UCSF Cancer Center. Scientific Collaborator

Beth Crawford, M.S., L.C.G.C.

Director of Genetic Counseling at the UCSF Cancer Genetics and Prevention Program. Scientific Collaborator

Laura Esserman, M.D., M.B.A.

Breast surgeon and Director of the UCSF Carol Franc Buck Breast Care Center. Scientific Collaborator

Susan Domchek, M.D.

Executive Director for the Basser Center for BRCA at Penn’s Abramson Cancer Center.Scientific Collaborator

Iftikhar J. Kullo, M.D

Professor, College of Medicine, Mayo Clinic. Director FH and Early Atherosclerosis Clinics. Head, Atherosclerosis and Lipid Genomics Laboratory. Advisor, Scientific Collaborator

Steve Laszlo Bock

Former SVP of People Operations at Google and author of “Work Rules!”Advisor

Stan Lapidus

CEO, Founder of SynapDx. Teaches at MIT and holds over 30 issued US patents.Advisor

Have more questions? Visit Provider Support.

* Certain exceptions apply. Variants will not be confirmed if, after testing, there is insufficient DNA available for secondary confirmation. Variants called at high confidence ( will be reported without secondary confirmation if the variant has been confirmed at least three times in previous carriers.